TTM Technologies Q1 Earnings Summary

Below are the earnings highlights for TTM Technologies (TTMI):

Earnings: -$5.81 million in Q1 vs. $17.25 million in the same period last year.
EPS: -$0.06 in Q1 vs. $0.17 in the same period last year.
Excluding items, TTM Technologies reported adjusted earnings of $18.65 million or $0.18 per share for the period.

Analysts projected $0.19 per share
Revenue: $544.44 million in Q1 vs. $581.26 million in the same period last year.

-Guidance:
Next quarter EPS guidance: $0.17 – $0.23
Next quarter revenue guidance: $530 – $570 Mln

Genworth Financial Inc. Bottom Line Falls In Q1

Genworth Financial Inc. (GNW) announced a profit for first quarter that decreased from last year

The company’s earnings came in at $62 million, or $0.12 per share. This compares with $191 million, or $0.37 per share, in last year’s first quarter.

Excluding items, Genworth Financial Inc. reported adjusted earnings of $84 million or $0.17 per share for the period.

The company’s revenue for the quarter fell 2.1% to $1.85 billion from $1.89 billion last year.

Genworth Financial Inc. earnings at a glance (GAAP) :

-Earnings (Q1): $62 Mln. vs. $191 Mln. last year.
-EPS (Q1): $0.12 vs. $0.37 last year.
-Revenue (Q1): $1.85 Bln vs. $1.89 Bln last year.

Gildan Activewear Inc. Q1 Profit Decreases, misses estimates

Gildan Activewear Inc. (GIL.TO) released a profit for first quarter that decreased from last year and missed the Street estimates.

The company’s bottom line totaled $97.6 million, or $0.54 per share. This compares with $146.4 million, or $0.77 per share, in last year’s first quarter.

Excluding items, Gildan Activewear Inc. reported adjusted earnings of $81.6 million or $0.45 per share for the period.

Analysts on average had expected the company to earn $0.51 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

The company’s revenue for the quarter fell 9.3% to $702.9 million from $774.9 million last year.

Gildan Activewear Inc. earnings at a glance (GAAP) :

-Earnings (Q1): $97.6 Mln. vs. $146.4 Mln. last year.
-EPS (Q1): $0.54 vs. $0.77 last year.
-Analyst Estimates: $0.51
-Revenue (Q1): $702.9 Mln vs. $774.9 Mln last year.

Noble Corp. Q1 Earnings Summary

Below are the earnings highlights for Noble Corp. (NE):

Earnings: $108 million in Q1 vs. -$37 million in the same period last year.
EPS: $0.74 in Q1 vs. -$0.54 in the same period last year.
Excluding items, Noble Corp. reported adjusted earnings of $27 million or $0.19 per share for the period.

Analysts projected $1.11 per share
Revenue: $610 million in Q1 vs. $210 million in the same period last year.

-Guidance:
Full year revenue guidance: $2.35 to $2.55 Bln

E. 13th Ave. in Denver’s Capitol Hill reopens after officers contact suspect

There was a large police presence in Denver’s Capitol Hill neighborhood where officers contacted “a wanted suspect” and East 13th Avenue was shut down between Grant and Logan streets.

The Denver Police Department said in a 4:50 p.m. tweet that the incident was in the 1300 block of Grant Street.

At 6 p.m. police said on Twitter that the suspect was in custody and the scene would be cleared shortly.

Sign up to get crime news sent straight to your inbox each day.

National Australia Bank H1 Net Profit Rises

National Australia Bank Ltd. (NAUBF.PK,NABZY.PK, NAB.AX) reported that its net profit attributable to owners of NAB for the first-half of fiscal year 2023 rose to A$3.97 billion from A$3.55 billion in the prior year. On a per share basis, net income was 121.2 cents up from 104.8 cents in the previous year.

Cash earnings for the period were A$4.07 billion up 17.0% from prior year. Cash earnings per share were 124.3 cents compared to 102.8 cents last year.

Net interest income rose to A$8.48 billion from A$7.09 billion in the previous year.

Revenue increased by 19.3%. Excluding the impact of the Citi consumer business, revenue increased by 16.6% mainly reflecting higher margins combined with stronger volumes and Markets & Treasury (M&T) income.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Airbus Q1 Profit Drops; Backs FY23 Outlook

Airbus (EADSF.PK,EADSY.PK) reported that its net income for the first quarter dropped to 466 million euros from last year’s 1.22 billion euros, with earnings per share declining to 0.59 euros from 1.55 euros in the prior year.

The financial result was 149 million euros compared to 166 million euros. It mainly reflects a positive impact from the revaluation of certain equity investments, partly offset by negative impacts from the revaluation of financial instruments and the net interest result.

Consolidated EBIT Adjusted decreased to 773 million euros from 1.26 billion euros in the previous year.

Consolidated revenues for the first quarter slightly decreased to 11.76 billion euros from last year’s 12.0 billion euros.

A total of 127 commercial aircraft were delivered compared to 142 aircraft in the prior year. The latest quarter delivery comprise of 10 A220s, 106 A320 Family, 6 A330sand 5 A350s.

The company said its 2023 guidance is unchanged with commercial aircraft deliveries expected to be backloaded.

The company targets to achieve in 2023 around 720 commercial aircraft deliveries and EBIT Adjusted of 6.0 billion euros.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

FDA Approves GSK's Arexvy, World's First RSV Vaccine For Older Adults

The U.S. Food and Drug Administration approved GSK Plc.’s (GSK.L,GSK) Arexvy, the world’s first respiratory syncytial virus or RSV vaccine for older adults.

Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including those with underlying medical conditions, and in those with severe RSV disease.

GSK said that, in June 2023, the Advisory Committee on Immunization Practices will make recommendations on the appropriate use of the vaccine in the US.

The vaccine will be available for older adults before the 2023/24 RSV season, which typically starts ahead of the winter months.

For More Such Health News, visit rttnews.com